Creative Medical Technology (CELZ)

Its programs span immunology, endocrinology, urology, neurology, orthopedics, and reproductive medicine. Creative Medical’s pipeline includes ImmCelz, also known as CELZ-100, a personalized immune therapy platform designed to modify a patient’s immune cells with the aim of improving therapeutic response. The company is also advancing AlloStem, or CELZ-201-DDT, and CREATE-1, a program targeting recent-onset Type 1 diabetes.

Beyond diabetes and immune therapy, Creative Medical has developed regenerative approaches for spine-related pain, sexual health, infertility, and organ-related disorders. Its portfolio includes AlloStemSpine for lower back pain, Alova for infertility linked to premature ovarian failure, and other programs such as OvaStem, CaverStem, FemCelz, and StemSpine. These assets reflect the company’s strategy of building a broad platform around cellular repair, immune modulation, and tissue regeneration.

For investors, CELZ represents exposure to an early-stage regenerative medicine business where valuation is closely tied to clinical progress, regulatory outcomes, financing needs, and the strength of its patent estate. Like many small biotechnology companies, Creative Medical carries high development risk, but its appeal lies in the potential breadth of its technology across multiple medical specialties.